2‑Deoxy‑D‑glucose enhances the anti‑cancer effects of idarubicin on idarubicin‑resistant P388 leukemia cells

Matsuo,Taisuke; Konya,Yumiko; Hirayama,Eri; Sadzuka,Yasuyuki

doi:10.3892/ol.2020.11616

2‑Deoxy‑D‑glucose enhances the anti‑cancer effects of idarubicin on idarubicin‑resistant P388 leukemia cells

Authors:
- Taisuke Matsuo
- Yumiko Konya
- Eri Hirayama
- Yasuyuki Sadzuka
View Affiliations

Affiliations: Division of Advanced Pharmaceutics, Department of Clinical Pharmaceutical Sciences, School of Pharmacy, Iwate Medical University, Iwate 028‑3694, Japan
Published online on: May 13, 2020 https://doi.org/10.3892/ol.2020.11616
Pages: 962-966

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cancer cells switch from mitochondrial oxidative phosphorylation to glycolysis, even in the presence of normal oxygen concentrations. Inhibition of the glycolytic pathway is therefore a critical strategy in cancer therapy. A non‑metabolic glucose analog, 2‑deoxy‑D‑glucose (2‑DG), has been the focus of research on glycolytic inhibitors for use in cancer treatment. The current study examined the anti‑cancer effects of 2‑DG on idarubicin (IDA)‑resistant P388 (P388/IDA) leukemia cells. P388/IDA cells were established following continuous exposure of IDA to P388 cells. Characterization of P388/IDA cells revealed increased lactate production and glucose consumption compared with P388 parent cells. The results of a cell viability assay determined that 2‑DG induces higher toxicity in P388/IDA cells compared with P388 cells. Although 2‑DG also exhibits endoplasmic reticulum (ER) stress‑inducing activity, the cytotoxic effect of the ER stress inducer, tunicamycin, on P388/IDA cells was lower than that of P388 cells. A combination of 2‑DG and IDA enhanced P388/IDA cell death compared with each agent alone. The results indicated that P388 cells activated glycolysis after acquiring IDA resistance and therefore, inhibition of the glycolytic pathway via 2‑DG might be a useful strategy for cancer therapy against IDA‑ resistant leukemia cells.

View Figures

View References

1	Gewirtz DA: A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol. 57:727–741. 1999. View Article : Google Scholar : PubMed/NCBI
2	Minotti G, Menna P, Salvatorelli E, Cairo G and Gianni L: Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 56:185–229. 2004. View Article : Google Scholar : PubMed/NCBI
3	McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM and Yellon DM: Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther. 31:63–75. 2017. View Article : Google Scholar : PubMed/NCBI
4	Nooter K, Sonneveld P, Oostrum R, Herweijer H, Hagenbeek T and Valerio D: Overexpression of the mdr1 gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin-A. Int J Cancer. 45:263–268. 1990. View Article : Google Scholar : PubMed/NCBI
5	Berman E and McBride M: Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood. 79:3267–3273. 1992. View Article : Google Scholar : PubMed/NCBI
6	Zhou XW, Xia YZ, Zhang YL, Luo JG, Han C, Zhang H, Zhang C, Yang L and Kong LY: Tomentodione M sensitizes multidrug resistant cancer cells by decreasing P-glycoprotein via inhibition of p38 MAPK signaling. Oncotarget. 8:101965–101983. 2017. View Article : Google Scholar : PubMed/NCBI
7	Mankhetkorn S, Dubru F, Hesschenbrouck J, Fiallo M and Garnier-Suillerot A: Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells. Mol Pharmacol. 49:532–539. 1996.PubMed/NCBI
8	Roovers DJ, van Vliet M, Bloem AC and Lokhorst HM: Idarubicin overcomes P-glycoprotein-related multidrug resistance: Comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines. Leuk Res. 23:539–548. 1999. View Article : Google Scholar : PubMed/NCBI
9	Vander Heiden MG, Cantley LC and Thompson CB: Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
10	Orang AV, Petersen J, McKinnon RA and Michael MZ: Micromanaging aerobic respiration and glycolysis in cancer cells. Mol Metab. 23:98–126. 2019. View Article : Google Scholar : PubMed/NCBI
11	Gu L, Yi Z, Zhang Y, Ma Z, Zhu Y and Gao J: Low dose of 2-deoxy-D-glucose kills acute lymphoblastic leukemia cells and reverses glucocorticoid resistance via N-linked glycosylation inhibition under normoxia. Oncotarget. 8:30978–30991. 2017. View Article : Google Scholar : PubMed/NCBI
12	Pelicano H, Martin DS, Xu RH and Huang P: Glycolysis inhibition for anticancer treatment. Oncogene. 25:4633–4646. 2006. View Article : Google Scholar : PubMed/NCBI
13	Garg AD, Maes H, van Vliet AR and Agostinis P: Targeting the hallmarks of cancer with therapy-induced endoplasmic reticulum (ER) stress. Mol Cell Oncol. 2:e9750892014. View Article : Google Scholar : PubMed/NCBI
14	DeSalvo J, Kuznetsov JN, Du J, Leclerc GM, Leclerc GJ, Lampidis TJ and Barredo JC: Inhibition of Akt potentiates 2-DG-induced apoptosis via downregulation of UPR in acute lymphoblastic leukemia. Mol Cancer Res. 10:969–978. 2012. View Article : Google Scholar : PubMed/NCBI
15	Badiner GJ, Moy BC, Smith KS, Tarpley WG, Groppi VE and Bhuyan BK: P388 leukaemia cells resistant to the anthracycline menogaril lack multidrug resistant phenotype. Br J Cancer. 62:378–384. 1990. View Article : Google Scholar : PubMed/NCBI
16	Kiue A, Sano T, Naito A, Inada H, Suzuki K, Okumura M, Kikuchi J, Sato S, Takano H, Kohno K, et al: Reversal by two dihydropyridine compounds of resistance to multiple anticancer agents in mouse P388 leukemia in vivo and in vitro. Jpn J Cancer Res. 81:1057–1064. 1990. View Article : Google Scholar : PubMed/NCBI
17	Aboudkhil S, Henry L, Zaid A and Bureau JP: Effect of testosterone on growth of P388 leukemia cell line in vivo and in vitro. Distribution of peripheral blood T lymphocytes and cell cycle progression. Neoplasma. 52:260–266. 2005.PubMed/NCBI
18	Matsuo T and Sadzuka Y: Extracellular acidification by lactic acid suppresses glucose deprivation-induced cell death and autophagy in B16 melanoma cells. Biochem Biophys Res Commun. 496:1357–1361. 2018. View Article : Google Scholar : PubMed/NCBI
19	Song K, Li M, Xu X, Xuan LI, Huang G and Liu Q: Resistance to chemotherapy is associated with altered glucose metabolism in acute myeloid leukemia. Oncol Lett. 12:334–342. 2016. View Article : Google Scholar : PubMed/NCBI
20	Staubert C, Bhuiyan H, Lindahl A, Broom OJ, Zhu Y, Islam S, Linnarsson S, Lehtiö J and Nordström A: Rewired metabolism in drug-resistant leukemia cells: A metabolic switch hallmarked by reduced dependence on exogenous glutamine. J Biol Chem. 290:8348–8359. 2015. View Article : Google Scholar : PubMed/NCBI
21	Miwa H, Shikami M, Goto M, Mizuno S, Takahashi M, Tsunekawa-Imai N, Ishikawa T, Mizutani M, Horio T, Gotou M, et al: Leukemia cells demonstrate a different metabolic perturbation provoked by 2-deoxyglucose. Oncol Rep. 29:2053–2057. 2013. View Article : Google Scholar : PubMed/NCBI
22	Raez LE, Papadopoulos K, Ricart AD, Chiorean EG, Dipaola RS, Stein MN, Rocha Lima CM, Schlesselman JJ, Tolba K, Langmuir VK, et al: A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 71:523–530. 2013. View Article : Google Scholar : PubMed/NCBI
23	Stein M, Lin H, Jeyamohan C, Dvorzhinski D, Gounder M, Bray K, Eddy S, Goodin S, White E and Dipaola RS: Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies. Prostate. 70:1388–1394. 2010. View Article : Google Scholar : PubMed/NCBI
24	Maximchik P, Abdrakhmanov A, Inozemtseva E, Tyurin-Kuzmin PA, Zhivotovsky B and Gogvadze V: 2-Deoxy-D-glucose has distinct and cell line-specific effects on the survival of different cancer cells upon antitumor drug treatment. FEBS J. 285:4590–4601. 2018. View Article : Google Scholar : PubMed/NCBI
25	Reyes R, Wani NA, Ghoshal K, Jacob ST and Motiwala T: Sorafenib and 2-deoxyglucose synergistically inhibit proliferation of both sorafenib-sensitive and -resistant HCC cells by inhibiting ATP production. Gene Expr. 17:129–140. 2017. View Article : Google Scholar : PubMed/NCBI